Raquel M. F.
- Country
- Spain
- Department
- Oncology
Research Overview
- Efficacy and Safety of PF-08634404 Plus Combination Therapy Versus Pembrolizumab Plus Combination Therapy in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
- A Phase 3 Randomized Open-Label Study Comparing Sigvotatug Vedotin and Docetaxel in Adults with Previously Treated Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 162 of 416 partner sites.
Specializations
Lung Cancer Specialization
The investigator demonstrates extensive expertise in treating various forms of non-small cell lung cancer (NSCLC), with particular focus on both resectable and non-resectable cases. Their research encompasses advanced and metastatic NSCLC treatments, including specialized approaches for Pancoast tumors.
- NSCLC Treatment Modalities
- Thoracic Oncology
- Surgical Oncology
Therapeutic Approaches
The investigator's work combines multiple treatment modalities including immunotherapy, chemotherapy, and targeted therapies. They have particular interest in novel therapeutic combinations and maintenance treatments, including expertise with agents such as atezolizumab and pembrolizumab.
- Combination Therapy
- Multimodal Treatment
- Personalized Medicine
Advanced Cancer Research
Their research portfolio includes investigation of biomarker-driven treatments and molecular targeted therapies, particularly in EGFR-mutated cancers. The investigator works extensively with circulating tumor DNA analysis and precision medicine approaches.
- Molecular Diagnostics
- Treatment Resistance
- Clinical Outcomes
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.